重组蛋白rcFAM3A在制备预防和 / 或治疗肾脏纤维化药物中的应用
By overexpressing the recombinant protein rcFAM3A, a drug for the prevention and treatment of renal fibrosis was prepared, which solved the problem of insufficient treatment for renal fibrosis in the existing technology, significantly reduced the degree of renal fibrosis, and improved the expression of renal tubular injury and fibrosis markers.
CN118976098BActive Publication Date: 2026-07-17THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
- Filing Date
- 2024-09-14
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current technologies offer limited treatment options for renal fibrosis, and there is a lack of effective prevention and treatment methods.
Method used
Using recombinant protein rcFAM3A, drugs for the prevention and/or treatment of renal fibrosis can be prepared by overexpressing FAM3A, including pharmaceutically acceptable dosage forms in injectable formulations.
Benefits of technology
Recombinant protein rcFAM3A significantly alleviated renal fibrosis caused by unilateral ureteral ligation or ischemia-reperfusion, reduced the expression of fibrosis markers, improved renal tubular injury, enhanced E-cadherin expression, inhibited the expression of TGF-β1 and collagen, and reduced the degree of renal fibrosis.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN118976098B_ABST
Abstract
本发明涉及一种生物医药领域，具体涉及重组蛋白rcFAM3A在制备预防和 / 或治疗肾脏纤维化药物中的应用。本发明创新地研究表明，重组蛋白rcFAM3A能够诱导FAM3A过表达，如此可以有效预防和 / 或治疗肾脏纤维化药物。
Need to check novelty before this filing date? Find Prior Art